Deal Team

Corporate
Antitrust
Executive Compensation and Benefits
Litigation
Real Estate M&A
Restructuring and Finance
Intellectual Property
Tax

Teva in the proposed divesture of its active-pharmaceutical ingredient (API) business

On January 31, 2024, Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or “TAPI”. TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide.

Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Teva.